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We amplified by polymerase chain reaction the heavy- and light-chain antibody genes of a human hybridoma secreting
a neutralizing, IgG monoclonal antibody to the G2 protein of Puumala virus. The heavy- and light-chain genes were cloned
and sequenced and the deduced amino acids were aligned with those of other human antibodies to identify the constant
and variable regions. The genes were cloned into the baculovirus plasmid transfer vector pACUW51 such that the heavy-
chain and light-chain genes were under control of the baculovirus polyhedrin or p10 promoters, respectively. The transfer
vector plasmid was cotransfected into cultured Spodoptera frugiperda (Sf9) cells with linearized DNA of the baculovirus
Autographa californica nuclear polyhedrosis virus, and recombinant baculoviruses were selected by plaque formation on
monolayers of Sf9 cells. Expression and secretion of an IgG monoclonal antibody was confirmed by assay of recombinant-
infected Sf9 cell supernatants for the presence of the heavy and light chains. Specificity of the expressed human antibody
was determined by immune-precipitation of radiolabeled Puumala virus proteins and by ELISA with Puumala virus-infected
cell lysates. Similar quantities of the expressed IgG and the authentic monoclonal antibody neutralized Puumala virus in
plaque-reduction neutralization assays. Neither the authentic nor the recombinant antibody could passively protect hamsters
from challenge with Puumala virus; however, our results demonstrate the potential of this methodology for production of
biologically active neutralizing antibodies. q 1997 Academic Press
INTRODUCTION patients. There are no known contraindications for anti-
body therapy for PUUV infections. Of concern is the pos-
Viruses in the Hantavirus genus, family Bunyaviridae, sibility of immune-complex formation which might exac-
cause two serious and sometimes fatal diseases: hanta- erbate disease. In studies of HFRS patients in Scandina-
virus pulmonary syndrome (HPS) and hemorrhagic fever via, immune complexes were detected in circulation
with renal syndrome (HFRS). Hantaviruses are carried by (Penttinen et al., 1981), but only slight deposition of anti-
a variety of rodents and are transmitted in infectious bodies and complement were seen in kidneys. These
aerosols of their urine, feces, and saliva. At least four depositions did not correlate with the extensive tissue
distinct hantaviruses cause HFRS: Hantaan virus (HTNV), damage observed in some patients and it was concluded
Puumala virus (PUUV), Seoul virus, and Dobrava-Bel- that immune complexes could not be the primary patho-
grade virus (Antoniadis et al., 1996; Lee and Dalrymple, logical mechanism of the glomerulonephritis observed
1989). Therapy for HFRS generally consists of supportive (Jokinen et al., 1977, 1978; Temonen et al., 1996). A cell-
care which may include renal or peritoneal dialysis (Zeier mediated immunopathology, however, has been sug-
et al., 1990; Van Ypersele de Strihou and Mery, 1989). gested (Temonen et al., 1996).
The drug ribavirin statistically improves HFRS disease Additional support for immune intervention for HFRS
outcome but is not always effective (Huggins et al., 1991). comes from studies in hamsters and rats. In both spe-
Antibody therapy for HFRS has not been studied in cies, passive transfer of neutralizing monoclonal antibod-
controlled clinical trials. Hantaviruses have been isolated ies (MAb) or polyclonal sera protected the animals from
from HFRS patients’ blood, thus it is clear that viremia challenge (Antoniadis et al., 1989; Arikawa et al., 1992;
coincides with illness (Sheshberadaran et al., 1988; An- Schmaljohn et al., 1990; Zhang et al., 1989). We also
toniades et al., 1987). It is logical, therefore, to infer that demonstrated that a neutralizing MAb to the G2 protein
it may be possible to interrupt the course of disease of HTNV can cure an infection of hamsters when adminis-
by administering neutralizing human antibodies to HFRS tered 1, 2, 3, and 4 days after infection (Liang et al., 1996).
To attempt to generate reagents for human immune-
therapy, we first studied the possibility of using human1 Present address: Institute of Virology, Chinese Academy of Preven-
Fab fragments expressed in bacteria (Liang et al., 1996).tive Medicine, 100 Ying Xin Jie, Xuan Wu Qu, Beijing 10052, China.
Results of those studies indicated that, although the Fabs2 To whom correspondence and reprint requests should be ad-
dressed. Fax: (301) 619-2439. E-mail: CSchmaljohn@Detrick.Army.Mil neutralized HTNV in vitro, they failed to protect hamsters
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from challenge with homologous virus. We theorized that Construction of the baculovirus transfer vector
plasmid and recombination with AcNPV virusthe Fc region of IgG may be required for passive protec-
tion. In this paper, we describe the cloning and baculovi-
Recombinant baculoviruses were prepared by homolo-rus-expression of a complete IgG monoclonal antibody
gous recombination using MAxBac reagents (Invitrogen)to Puumala virus. We also describe experiments aimed
and the transfer vector pACUW51 which had the lightat determining if the expressed antibody can neutralize
chain under control of the p10 promoter and the heavyPUUV in cell culture assays and passively protect ham-
chain under control of the polyhedrin promoter (Weyersters from challenge.
et al., 1990) (Pharmingen). Positive recombinant clones
were detected by DNA hybridization. Expressed IgG was
MATERIALS AND METHODS detected by sandwich ELISA with goat anti-human Fab-
specific or anti-human Fc-specific antibodies (Sigma).Viruses, cells, media, and hybridomas
PUUV, strains P360, K27 (Sheshberadaran et al., 1988), Radiolabeling and immune precipitation
and Sotkamo (Schmaljohn et al., 1985; Vapalahti et al.,
Monolayers of Sf9 cells in 25-cm2 flasks were infected1992), was propagated in Vero-E6 cells (ATCC C1008,
with 1 ml of the recombinant baculovirus (1.5 1 107 PFU),CRL1586). The P360 and K27 strains were previously
radiolabeled from 1 to 22 hr after infection with 200 mCidetermined to be nearly identical (Xiao et al., 1993) and
of 35S Promix (Amersham), and recovered by binding towere used interchangeably in these studies. Virus was
protein A–Sepharose. Authentic PUUV proteins were ra-concentrated by precipitation with polyethylene glycol
diolabeled and immune precipitated, and gel electropho-and purified by sucrose gradient sedimentation as pre-
resis was performed as described earlier for HTNV (Ari-viously described (Schmaljohn et al., 1983). The hybrid-
kawa et al., 1989).oma cell lines secreting neutralizing MAb to PUU G2,
1C9, 2E8, and 2F10 were described previously (Lundkvist
Purification of IgGet al., 1993). Briefly, Epstein–Barr virus-transformed hu-
man spleen cells, from a PUUV-immune donor, were Sf9 cells, grown in suspension in serum-free medium
fused with a human 1 mouse hetrohybridoma (SPAM-8) (Gibco), were infected at an m.o.i. of 10 with the recombi-
to yield human 1 (human 1 mouse) triomas secreting nant baculovirus and incubated until approximately 50%
antibodies to PUUV (Gustaffson et al., 1991; Lundkvist et cell death was observed (4 to 5 days postinfection). The
al., 1993). human hybridoma cell line, 1C9, was cultured as a mono-
layer in 150-cm2 flasks in OptiMEM medium (Gibco) sup-
Synthesis of the IgG heavy and light chain gene plemented with 6% fetal bovine serum. Supernatants
coding regions were harvested when approximately 50% of the hybrid-
oma cells had died (5–7 days after confluency). The su-
Total cellular RNA was isolated from pelleted hybrid-
pernatants of recombinant virus-infected Sf9 cells and
oma cells by using Trizol reagent (Gibco) according to
hybridoma cells were clarified by centrifugation then fil-
the manufacturer’s directions. cDNA was synthesized by
tered through 0.45 mM filters and concentrated 10-fold
using oligo dT primers and reverse transcriptase (Boeh-
by using Centricon-10 filters (Amicon). The concentrated
ringer). Initially, the heavy chain Fd and light chain genes
supernatants were applied to a protein G–Sepharose
(Fab genes) were amplified using primers VH3a, VL3
CL-4B (Sigma) affinity column and IgG was eluted with
CG1z, and CL2, reported by Kang et al. (1991). The PCR
1.0 M glycine–HCl, pH 2.7. IgG concentrations were esti-
products were cloned into pComb3 (Barbas et al., 1991)
mated by using the formula: Protein concentration (mg/
and expressed in bacteria as described previously for
ml)  (1.55 1 A280) 0 (0.76 1 A260) (Harlow and Lane,
murine Fab fragments to Hantaan virus (Liang et al.,
1988). Approximately 10 mg of each IgG preparation was
1996). To amplify the entire heavy chain for baculovirus
examined by SDS–PAGE as previously described
expression, primers were designed to add a eucaryotic
(Schmaljohn et al., 1983).
signal sequence to the genes. Thirty-five PCR cycles
were performed each consisting of 947 for 1 min, 527 for ELISA
1 min, and 727 for 3 min. The resultant PCR products
were cloned into pCR II (Invitrogen). To verify expression, Sucrose gradient-purified PUUV (Schmaljohn et al.,
1983) was diluted in phosphate-buffered saline (PBS), pHtransient assays, in cell cultures infected with a recombi-
nant vaccinia virus expressing T7 polymerase, were per- 7.4, and 100 ml was added to each well of flat-bottomed
96-well microtiter plates, and incubated at 47 overnight.formed as reported earlier (Fuerst et al., 1986). Nucleo-
tide sequences were determined as described pre- The plates were washed 3 times with PBS containing
0.05% Tween 20, and 100 ml of twofold dilutions of 30viously (Liang et al., 1996), and the complementarity
determining regions (CDRs) were located by comparing mg/ml preparations of the purified IgG or expressed IgG
was added to the wells. The plates were incubated atsequences to those reported previously (Padlan, 1994).
AID VY 8695 / 6a3f$$$302 07-31-97 08:25:36 vira AP: VY
254 LIANG ET AL.
377 for 1.5 hr and then washed as above. A 1:1600 dilution Passive protection of hamsters
of HRP-conjugated anti-human IgG Fc (100 ml/well)
Two protection experiments that differed in the chal-(Sigma) was then added and the plates were incubated
lenge strains of PUUV (strains K27 or Sotkamo) wereat 377 for 1 hr. After washing, 100 ml of ABTS peroxidase
conducted. For the K27 challenge experiment, approxi-substrate (Kirkegaard & Perry, Gaithersburg, MD) was
mately 200 or 70 mg of purified IgG from the G2-specificadded and the plates were incubated for 20 min at room
neutralizing MAb, 1C9, or approximately 70 mg of thetemperature.
baculovirus expressed IGg, or 70 mg of IgG purified from
a control pool of human sera, were each passively ad-
Assay for IgG expression, secretion, and ministered by intraperitoneal injection (im) to four female
accumulation 8- to 10-week-old outbred Syrian hamsters (Charles River
Breeding Laboratories, Inc., Wilmington, MA). Control
Approximately 2.4 1 106 Sf9 cells were seeded in T25 hamsters received 200 ml of PBS without antibodies. For
flasks and allowed to attach for 1 hr. The nearly confluent the Sotkamo challenge experiment, four hamsters each
monolayers were infected with 1 ml of 1.5 1 107/ml re- were given two doses of 200 mg of purified 1C9 antibody
combinant baculovirus. After incubation for 2 hr, the vi- or the expressed antibody 5 hr before infection and again
rus-containing medium was removed from flasks and re- 3 days later (total antibody transferred was 400 mg). Four
placed with fresh SF900 medium. The flasks were incu- additional hamsters each received two doses of 200 mg
bated at 287 for 1–7 days without medium change. One of purified IgG from a convalescent human HFRS patient
infected T25 flask was harvested each 24 hr. Superna- from Sweden, and four hamsters received two doses of
tants were stored at 47 and cells were counted and as- PBS. Five hours after transfer, the hamsters were anes-
sayed for viability by trypan blue staining. Capture ELISA thetized and bled by cardiac puncture then challenged
was used to detect secreted IgG. Briefly, purified anti- by im injection of 1000 PFU of PUUV. The hamsters chal-
human Fab antibody (Sigma) was diluted 1:1600 and 100 lenged with strain K27 were again bled at Days 3 and
ml was applied to the wells of 96-well ELISA plates. After 28 after challenge, and the hamsters challenged with
overnight incubation at 47, 100 ml of twofold dilutions of strain Sotkamo were bled 28 days after challenge. The
the purified IgG or the expressed IgG (starting at 7.5 mg/ hamsters were then killed and lung tissues were har-
ml protein concentration) or dilutions of the Sf9 superna- vested for RT-PCR analysis.
tants was added to the wells. The ELISA was then contin- Approximately 25 mg of each tissue sample were ho-
ued as described above. The quantity of expressed IgG mogenized in 4 ml of Trizol reagent (Gibco). RT-PCR was
secreted from Sf9 cells for every 24 hr was estimated performed essentially as described previously (Chu et
according to the following formula: mg IgG/cell  (the al., 1995), except for the following modifications. Sixty
IgG dilution required to yield OD410 of 0.4–0.5) (mg/ml of picomoles of each outer primer was annealed to the RNA
purified IgG required to yield OD410 of 0.4–0.5) (ml of for reverse transcription. Ten microliters of first strand
supernatant for each flask)/number of cells. reaction was used for the first round of PCR. First round
PCR consisted of thirty-five thermo-cycles of 40 sec at
947, 40 sec at 507, and 2 min at 727. The second roundPlaque reduction neutralization test (PRNT80) with
conditions were the same except that the annealing tempexpressed IgG
was 557. The outer forward and reverse primers used for
strain K27 amplification were 5* GGACCAGGTGCAGAT-PRNT80 was performed on Vero-E6 cell monolayers in
TGTGAAGC 3* and 5* ACTTCACAAACCATTGAACC 3*.6-well tissue culture plates by using methods similar to
The inner forward and reverse primers were 5* GTGTCC-those published formerly (Arikawa et al., 1989). Briefly,
AGAGATTCCGTGGT 3* and 5* GAACATAAGTATGCG-the purified antibodies were standardized to 60 mg/ml
AATGCAA 3*. The outer forward and reverse primersand were serially diluted in twofold or fourfold incre-
used for strain Sotkamo amplification were 5* GGACCA-ments. The diluted antibodies were incubated with 100
GGTGCAGACTGTGAAGC 3* and 5* ACCTCACAAACC-PFU of PUUV, strain P360, at 377 for 1 to 2 hr. Virus-
ATTGAGCC 3*. The inner forward and reverse primersantibody mixtures were applied to cell monolayers in 6-
were 5* GTGTTCAAAGATTCCGTGGT 3* and 5* GAG-well plates and incubated at 377 for 1 hr and then overlaid
CAAAGATATGCAAATGCAA 3*.with EMEM containing 0.6% agarose (Seakem ME, FMC
Corp). After incubation at 377 for 10 days, a second over-
RESULTSlay identical to the first except for the addition of neutral
red (final concentration 0.167 mg/ml) was added. The Cloning of the antibody genes
neutralizing antibody titer was calculated as the recipro-
cal of the highest dilution resulting in an 80% reduction of We first PCR-amplified and cloned only the Fd region
plaques as compared to wells containing virus incubated of the heavy-chain genes and the complete light-chain
genes from the three hybridoma cell lines, 1C9, 2E8,with sera from uninfected hamsters.
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and 2F10 (Lundkvist et al., 1993), by using primers that
generated appropriate restriction sites for ligation to the
phagemid, pComb3 (Kang et al., 1991; Barbas et al.,
1991). This allowed us to readily express the Fab frag-
ments in bacteria (data not shown) and to determine
the nucleotide sequences of the variable regions of the
genes. The nucleotide sequences determined for the
heavy- and light-chain gene variable regions were identi-
cal for all three MAb and were deposited in Genbank
(Accession numbers U96043 and U96044). Thus, for re-
maining studies we used only one of the identical hybrid-
oma cell lines, 1C9.
Because the primers that we used initially were de-
signed for bacterial expression, it was necessary to
reamplify the genes with different primers. These prim-
ers added eukaryotic signal sequences to the heavy-
and light-chain genes. To design the primers, we com-
pared the nucleotide sequences of the variable gene
regions of 1C9 to those in Genbank. Primers with se-
quences corresponding to the signal sequences of
antibody genes with variable regions similar to those
of 1C9 were synthesized and used to amplify complete
heavy- and light-chain genes of 1C9. To confirm the
presence of the human signal sequences, the terminal
5* nucleotide sequences for both chains were deter-
mined (Fig. 1A). The deduced amino acid sequences
of the variable regions of the heavy- and light-chains
are shown in Fig. 1B.
Expression of IgG by the recombinant baculovirus
We assayed the recombinant baculoviruses for ex-
pression of the heavy- and light-chain antibody genes by FIG. 1. (A) Comparison of the 5* termini of heavy- and light-chain
genes expressed in bacteria or in AcNPV-infected Sf9 cells. The heavy-using an indirect immunofluorescent antibody test (IFAT)
and light-chain genes for bacterial expression were amplified by usingwith anti-human FC-specific antibody and by affinity chro-
oligonucleotide primers (listed above each gene sequence) corre-matography and polyacrylamide gel electrophoresis. Cy-
sponding to previously published sequences (Kang et al., 1991). The
toplasmic fluorescence of infected insect cells demon- XhoI or SacI restriction sites needed to facilitate cloning into pComb3
strated that a human antibody FC region was expressed are indicated by a single underline. The nucleotides indicated with a
double underline were derived from pComb3 and include the pelB(not shown). To determine if IgG was secreted from the
leader sequence. The . . . indicate 56 nucleotides not shown. Therecombinant-infected insect cells, supernatants were
BamHI or Bgl II restriction sites needed to facilitate cloning into thecollected, concentrated, and recovered by binding to pro-
baculovirus transfer vector pAcUW51 are indicated by a single under-
tein G–Sepharose. Heavy and light chains of the ex- line. Reverse primers for the heavy- and light-chains, respectively, were
pected sizes were observed both for expressed and au- PUU-CH3-2: 5*-CGCGGATCCCTACTGCGTGTAGTGGTTGTGC-3* and
PUU-CL: -GAAGATCTAGAACTATGAACATTCTGTAGG-3. The ATG startthentic IgG (Fig. 2).
codons are indicated by bold type. (B) The deduced amino acids ofTo measure the IgG secreted by the recombinant ba-
the variable regions of the heavy- and light-chains are shown. Arrowsculovirus-infected Sf9 cells, supernatants were collected
indicate signal sequence cleavage sites. The CDR are underlined.
every 24 hr for 7 days. Cell viabilities were determined
each day and the antibody present in supernatants was
quantitated by ELISA using purified IgG as a reference mately 6 mg of each were required to yield an OD410 instandard. Although cell viability decreased, the quantity
excess of 0.5, indicating that the two antibodies had simi-
of IgG increased up to 72 hr after infection and then
lar binding properties (Fig. 4). To confirm the antigen
remained constant at about 9 mg/ml (Fig. 3). It was esti-
specificity of the expressed IgG, we immune-precipitated
mated that the maximum amount of IgG produced was
radiolabeled PUUV proteins. Both the authentic and ex-
13 mg/106 cells.
pressed MAb precipitated G2 and a larger band believed
Biological function of the expressed IgG to be a dimer of G2 or a heterodimer of G1 and G2 (Fig.
5). Comparing the neutralizing properties of the authenticWe compared the antigen binding characteristics of
the expressed vs the authentic MAb by ELISA. Approxi- and expressed MAb by PRNT revealed that approxi-
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FIG. 4. Comparison by ELISA of the binding characteristics of IgG
recovered from the supernatants of cultured hybridoma 1C9 (IgG) or
from the supernatants of recombinant baculovirus-infected Sf9 cells
FIG. 2. Polyacrylamide gel electrophoresis. The panel on the left
(IgGR).
displays Coomassie blue-stained antibodies that were recovered and
concentrated from the supernatants of cultured hybridoma cells (IgG)
or from recombinant baculovirus-infected Sf9 cells (IgGR) or from un-
hamsters at 21 days postchallenge; i.e., all hamsters hadconcentrated supernatants (Sup) of the infected insect cells. The panel
viral RNA in their lungs (Table 1). Thus, although IgG fromon the right displays radiolabeled antibody recovered from the recombi-
nant baculovirus-infected insect cells. The heavy-chains (HC) and light- both the 1C9 human hybridoma and the expressed IgG
chains (LC) are indicated with arrows. The sizes of molecular weight could neutralize PUUV in cell culture, neither protected the
markers (Mr) are indicated to the left of each panel. hamsters from viral challenge.
We repeated the passive transfer study, but changed
the conditions such that two doses of 200 mg of the MAbmately 0.1 mg of purified IgG of each MAb was required
were passively transferred at 5 hr before challenge andto achieve an 80% reduction in plaques (Fig. 6).
again 3 days after challenge. We also changed the strain
of PUUV used in challenge from the K27 strain (fromPassive transfer of antibodies to hamsters and
challenge with PUUV Russia) to the Sotkamo strain (from Finland) in order to
provide a challenge virus more similar to that encoun-
To determine if the authentic or baculovirus-expressed
tered by the spleen donor from which 1C9 was derived.
IgG could passively protect hamsters from challenge with
Again, although most hamsters displayed low levels of
PUUV, we performed two separate passive transfer and
circulating antibody at the time of challenge, only one
challenge experiments. In the first experiment, we trans-
hamster from the 1C9 hybridoma transfer group did not
ferred 200 or 70 mg of the 1C9 MAb or 70 mg of the baculovi-
have RNA in its lungs 28 days postinfection. A second
rus-expressed IgG to hamsters and challenged them 5 hr
hamster in the same group did not have a rise in antibody
later with 1,000 PFU of PUUV, strain K27. Circulating neu-
titer after infection, so was probably also partially pro-
tralizing antibodies were measured by PRNT just before
tected from the challenge (Table 2).
challenge and at 3 and 21 days after challenge. All ham-
sters had low-titer neutralizing antibodies before challenge.
DISCUSSION
After challenge, all but one of the hamsters developed very
high neutralizing antibody responses, suggesting that they Our previous studies demonstrated that, although neu-
tralizing mouse MAb could passively protect hamsterswere not protected from infection. This finding was con-
firmed by RT-PCR studies on lung tissue collected from the from challenge with HTNV, Fab fragments derived from
hybridomas secreting those mouse MAb and expressed
FIG. 5. Polyacrylamide gel electrophoresis of radiolabeled PuumalaFIG. 3. Accumulation of recombinant IgG in the supernatant of bacu-
lovirus-infected Sf9 cells. Medium was collected from 25-cm2 flasks virus proteins, immune-precipitated with: (1) polyclonal rabbit sera to
Puumala virus; (2) IgG from cultured hybridoma cells; (3) IgG fromeach day for 7 days after infection with the recombinant baculovirus
and analyzed for the presence of IgG by ELISA. The estimated amount recombinant baculovirus-infected Sf9 cells; (4) control rabbit sera. The
positions of Puumala virus nucleocapsid (N), envelope proteins (G1,of IgG per cell is indicated by the bar graph and the amount of IgG
per milliliter of supernatant is indicated by the line graph. The viability G2), and a band believed to be a dimer of G1 and G2 (X) are indicated
to the left of the autoradiograph.of cells at each time point is shown above the graph.
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TABLE 2
Passive Transfer of 1C9 MAb and Baculovirus-Expressed IgG
to Hamsters and Challenge with Puumala Virus, Strain Sotkamo
80%/50% PRNT
RNA in
Inoculuma hamster 5 hr 28 days lungs
1C9 IgG
1 10/20 80/160 0
2 10/10 ⁄320/⁄320 /FIG. 6. Plaque-reduction neutralization assay of IgG recovered from
3 10/80 10/£40 /the supernatants of cultured hybridoma 1C9 (IgG) or from the superna-
4 20/40 ⁄320/⁄320 /tants of recombinant baculovirus-infected Sf9 cells (IgGR). Serial dilu-
tions of each antibody were incubated with infectious Puumala virus
IgGRbefore plaque assay on monolayers of Vero E6 cells.
1 10/10 ⁄320/⁄320 /
2 10/10 ⁄320/⁄320 /
3 10/20 ⁄320/⁄320 /
in E. coli were not protective (Liang et al., 1996). We 4 10/40 ⁄320/⁄320 /
theorized that the inability of the Fabs to participate in
HFRS patient serumimmune mechanisms associated with an Fc region con-
1 10/20 ⁄320/⁄320 /
tributed toward their protection failure. Consequently, we 2 10/10 160/160 /
sought a means to generate complete IgG molecules 3 10/20 160/320 /
4 10/20 ⁄320/⁄320 /from cloned human antibody genes.
PBS
1 10/10 ⁄320/⁄320 /
TABLE 1 2 10/10 ⁄320/⁄320 /
3 10/10 ⁄320/⁄320 /Passive Transfer of 1C9 MAb and Baculovirus-Expressed IgG
to Hamsters and Challenge with Puumala Virus, Strain K27
a Hamsters received two doses of 200 mg of each antibody 5 hr
before challenge and 3 days after challenge.PRNT antibody
Inoculuma 3 28 RNA in
hamster 5 hr days days lungs In the studies reported here, we expressed a complete,
neutralizing human IgG to the G2 protein of PUUV, by
1C9 IgG (200 mg)
using a recombinant baculovirus and insect cell culture1 10 10 ⁄640 /
system. The major advantage of the baculovirus expres-2 40 10 ⁄640 /
3 10 10 ⁄640 / sion system is the simplicity of producing biologically
4 10 20 ⁄640 / functional antibodies in amounts useful for research pur-
poses. Both genes can be expressed from a single re-1C9 IgG (70 mg)
1 10 10 20 / combinant virus, thus facilitating both development and
2 ⁄40 ⁄20 ⁄640 / assay of secreted antibodies. Unlike bacterial or yeast
3 ⁄40 ⁄20 ⁄640 / expression systems, the MAb generated in insect cells
4 ⁄20 ⁄20 ⁄640 /
are correctly processed and folded. Qualitatively, the ba-
IgGR (70 mg) culovirus-expressed antibodies may differ slightly in gly-
1 10 10 ⁄640 / cosylation from antibodies produced in mammalian sys-
2 10 10 ⁄640 /
tems because insect cells do not perform certain carbo-3 10 10 ⁄640 /
hydrate trimming functions and do not process the4 10 10 ⁄640 /
sugars to add complex residues such as terminal sialic
Negative human serm (70 mg)
acid and galactose (O’Reilly et al., 1992). The importance1 nd 10 ⁄640 /
of these carbohydrate modifications were studied re-2 nd 10 ⁄640 /
3 nd 10 ⁄640 / cently with an antibody of the same isotype as the 1C9
4 nd 10 ⁄640 / antibody used in our report (i.e., IgG1). In those studies,
it was determined that removing terminal sialic acid resi-PBS
1 10 10 ⁄640 / dues from a human IgG1 MAb by glycopeptidase F diges-
2 10 10 ⁄640 / tion did not affect any of the tested IgG activities, includ-
3 10 10 ⁄640 / ing complement lysis activity and antibody-dependent
4 10 10 ⁄640 /
cell-mediated cytotoxicity. Complete removal of the car-
bohydrates, however, abolished both of those activitiesa Hamsters received two doses of 200 mg of each antibody 5 hr
before challenge and 3 days after challenge. (Boyd et al., 1995). Eliminating the majority of the galac-
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tose residues from the desialylated antibody reduced but afforded protection as judged by the appearance of
PUUV-specific RNA in the hamsters’ lungs. We suspectdid not abolish complement lysis activity. Other activities
were not affected by degalactosylation (Boyd et al., 1995). that these results indicate that our protection experi-
ments were being performed just at or slightly below theIn another study, a mouse MAb expressed with a recom-
binant baculovirus effectively bound complement compo- threshold of effectiveness for the 1C9 antibody. Because
we administered as much purified antibody as we couldnent C1q, suggesting that complement lysis remained
intact (zu Putlitz et al., 1990). In total, the qualitative as- practically produce, we were unable to determine if we
could surmount this threshold with more antibody. Evenpects of baculovirus-expressed antibodies are very simi-
lar to those of mammalian-expressed antibodies. if we were able to test higher amounts of antibody, pro-
tection may not have been achieved, because it appearsThe major drawback to using the baculovirus expres-
sion system for antibody production is that the baculovi- that hamster protection does not strictly correlate to virus
neutralization in cell culture. That is, the amount of anti-rus kills the insect cells; therefore, there is only a narrow
window of antibody production. Our recoveries of anti- body that we passively transferred was theoretically suffi-
cient to completely neutralize the infectious virus. Ac-body from the insect cell culture medium (approximately
9 mg/ml) are similar to those reported by others (Hase- cording to our PRNT results, as little as 0.02 mg of the
expressed 1C9 MAb neutralized 50% of plaques. Theman and Capra, 1991; Hu et al., 1995). With continuous
feed fermentors, it may be possible to obtain a more blood volume of the hamsters in our studies (approxi-
mately 6–8 weeks old) was about 8 ml. Therefore, trans-stable production of antibodies in a scale-up mode. Even
if scale-up is not possible, the baculovirus system is fer of 200 mg of the antibody should have resulted in 25
mg/ml of each antibody. We expected that this level ofmuch quicker than other eukaryotic systems for generat-
ing antibodies of interest, thus could be used for a mid- antibody would be sufficient for protection, if protection
could be strictly correlated with neutralization in cell cul-point evaluation of antibodies which appear to have po-
tential for scale-up. Other new developments in the use ture.
Another factor which may have contributed to the fail-of the baculovirus system include recently described
‘‘cassette baculoviruses’’ which can be used to generate ure of both antibodies to protect hamsters from challenge
is a cross-species incompatibility that results in poorhuman/mouse chimeric antibodies (Poul et al., 1995).
Such cassettes, with standard human Fc regions, could half-life of human antibodies in hamsters. Although we
did not determine the half-life of our antibodies, we doalso be developed to allow phage display and E. coli
expression of human Fabs of interest and subsequent not think this to be a major problem because we were
able to detect circulating neutralizing antibodies at 5 hrrapid cloning of selected fragments into the cassette
vectors. and at 3 days after transfer. It is also possible that ham-
ster Fc receptors recognize human antibodies poorly. WeIn the studies reported here, the genes for the IgG
molecule cloned were obtained from a human hybridoma did not test this directly and we were unable to find
other examples in the literature of the transfer of humanderived from spleen lymphocytes of a PUUV-immune in-
dividual (Lundkvist et al., 1993). This hybridoma was se- antibodies to hamsters.
Despite the absence of protection, our results clearlylected for gene cloning because it produced a neutraliz-
ing antibody to the G2 protein of PUUV that partially demonstrate that a biologically functional human anti-
body can be produced with recombinant baculoviruses.protected bank voles from challenge with PUUV (Lund-
kvist et al., unpublished information). We demonstrated Unlike E. coli-expressed Fabs, baculovirus-expressed
antibodies may function not only by neutralizing infec-that the baculovirus-expressed antibody was biologically
indistinguishable from the hybridoma-produced antibody tious virus, but may also contribute to cellular immune
mechanisms that require Fc regions such as opsiniza-in serological assays, and more importantly, that it neu-
tralized PUUV with the same kinetics as did the authentic tion, antibody-dependent-cellular-cytotoxicity, and activa-
tion of natural killer cells. Such mechanisms have beenMAb. These results are consistent with the studies men-
tioned above which indicate that whatever differences suggested to be important for protection from or clear-
ance of hantaviral infections (Asada et al., 1987, 1988,insect cell-derived antibodies may possess, these do not
appear to negatively influence common biological func- 1989; Nakamura et al., 1985). The baculovirus expressed
antibodies will also be more stable than Fabs becausetions of the antibodies.
Of course, the most important biological function of an of correct glycosylation and folding and will have a longer
half-life in circulation. These attributes suggest that bacu-antibody is its ability to protect from infection. Although,
in a preliminary study in hamsters, we were able to repro- lovirus-expressed antibodies may be useful in prophy-
laxis or therapy of HFRS.duce the protection results obtained with 1C9 antibody
in bank voles (not shown), two subsequent attempts to
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